STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides

RegulatoryapprovedBPC-157KPVPositive

AI Analysis

Summary

An FDA advisory panel narrowly voted to recommend allowing compounding pharmacies to produce the unapproved peptides BPC-157 and KPV, marking a regulatory win for RFK Jr. and advocates of these popular but unproven compounds.

Outcome Details

FDA advisory panel narrowly voted to recommend allowing compounding pharmacies to produce unapproved peptides BPC-157 and KPV

Importance:6/10

Sentiment:

0.60

FDA advisory panelcompounding pharmaciesunapproved peptidesRFK Jr.regulatory decision

Read the original article

Published by STAT News on July 23, 2026 8:08 PM

Read Original